TEZSPIRE (tezepelumab-ekko) 

Auto-injector: Self-Administered-subcutaneous injection

Vial/Prefilled syringe: Office-Administered – subcutaneous injection

Diagnosis considered for coverage:
  • Asthma - a thymic stromal lymphopoietin (TSLP) blocker, human monoclonal antibody (IgG2λ), indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.
    • Not for relief of acute bronchospasm or status asthmaticus.
Coverage Criteria:

For diagnosis of severe asthma:

  • Diagnosis of severe asthma; AND
  • Patient is age 12 years or older; AND
  • Prescribed by or in consultation with a pulmonologist or allergist/immunologist; AND
  • Medical record documents one of the following:
    • Patient has had two or more asthma exacerbations requiring systemic corticosteroids (e.g., prednisone) within the past 12 months OR
    • Prior asthma-related hospitalization within the past 12 months; AND
  • Patient is currently being treated with one of the following unless there is a contraindication or intolerance to these medications:
    • BOTH of the following:
      • High dose inhaled corticosteroid (ICS) (i.e., greater than 500 mcg fluticasone propionate equivalents per day)
      • Additional asthma controller medication (e.g., leukotriene receptor antagonist [LTRA][e.g., montelukast]; long acting beta-2 agonist [LABA][e.g., salmeterol]; long-acting muscarinic antagonist [LAMA][e.g., tiotropium], OR
    • One maximally-dosed combination ICS/LABA product (e.g., Advair [fluticasone propionate 500 mcg/salmeterol 50 mcg], Symbicort [budesonide 160 mcg/formoterol 4.5 mcg], Breo Ellipta [fluticasone 200 mcg/vilanterol 25 mcg]).
Reauthorization Criteria:

For diagnosis of severe asthma:

  • Documentation of positive clinical response to therapy as evidenced by ONE of the following:
    • A reduction in asthma exacerbations
    • Improvement in forced expiratory volume in 1 second (FEV1) from baseline
    • Decreased use of rescue medications; AND
  • Patient continues to be treated with an inhaled corticosteroid (ICS) (e.g., fluticasone, budesonide) with or without additional asthma controller medication (e.g., leukotriene receptor antagonist [LTRA] [e.g., montelukast], long-acting beta-2 agonist [LABA] [e.g., salmeterol], long-acting muscarinic antagonist [LAMA] [e.g., tiotropium]) unless there is a contraindication or intolerance to these medications; AND
  • Prescribed by or in consultation with a pulmonologist or allergist/immunologist.
Coverage Duration:
  • Initial: 6 months
  • Reauthorization: 1 year
Authorization is not covered for the following:
  • The use of this drug for indications not listed in this policy does not meet the coverage criteria established by the Western Health Advantage (WHA) Pharmacy and Therapeutics (P&T) Committee.
Additional Information:
  • TEZSPIRE vial and pre?filled syringe are intended for administration by a healthcare provider.
  • TEZSPIRE pre-filled pen can be administered by patients/caregivers or healthcare providers. Patients/caregivers may administer TEZSPIRE pre-filled pen after proper training in subcutaneous injection technique and after the healthcare provider determines it is appropriate.
Policy Updates:
  • 5/17/2022 – New policy.
  • 9/1/2024 (policy effective date) – New policy approved by WHA P&T Committee. (P&T 8/20/2024) (P&T Meeting August) 
References:
  1. Corren J, Gil EG, Griffiths JM, Parnes JR, van der Merwe R, Sa?apa K, O'Quinn S. Tezepelumab improves patient-reported outcomes in patients with severe, uncontrolled asthma in PATHWAY. Annals of Allergy, Asthma & Immunology. 2021 Feb 1;126(2):187-93.
  2. Menzies-Gow A, Colice G, Griffiths JM, Almqvist G, Ponnarambil S, Kaur P, Ruberto G, Bowen K, Hellqvist Å, Mo M, Garcia Gil E. NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma. Respiratory research. 2020 Dec;21(1):1-2.
  3. Tezspire Prescribing Information. Amgen Inc. Thousand Oaks, CA. December 2021.

 

Last review date: September 1, 2024

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone